← FDA DRUG APPROVALS

FDA ANDA · ANDA218459

SIPONIMOD

Sponsor: AUROBINDO PHARMA LTD

APPLICATION
ANDA218459
TYPE
ANDA
ORIGINAL APPROVAL
2026-03-06
LATEST ACTION
2026-03-06
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

SIPONIMODDiscontinued
SIPONIMOD EQ 2MG BASE · TABLET · ORAL
SIPONIMODDiscontinued
SIPONIMOD EQ 0.25MG BASE · TABLET · ORAL
SIPONIMODDiscontinued
SIPONIMOD EQ 1MG BASE · TABLET · ORAL

Approval history

2026-03-06UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →